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Abstract
Background: Hyperbilirubinemia is a common disorder during neonatal period in Taiwan. Gene variants may play
an important role in the development of neonatal hyperbilirubinemia. The current study investigated the association
between neonatal hyperbilirubinemia and common gene variants involving the production and metabolism of
bilirubin.
Methods: This prospective study enrolled 444 healthy infants born in the Chang Gung Memorial Hospital at Taipei
from 2013–2015. Hyperbilirubinemia was defined as a total bilirubin≥ 15 mg/dL. A log-binomial model was used to
assess the risk of gene variants.
Results: The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats)
(39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA
at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia
(5.0 %), and G6PD deficiency (3.2 %). The log-binomial analysis demonstrated greater risks of hyperbilirubinemia
in infants with GA at nt211 in UGT1A1 (RR = 1.548; 95 % CI = 1.096–2.187), short HO-1 promoter GT-repeat (RR = 2.
185; 95 % CI = 1.527–3.125), and G6PD deficiency (RR = 1.985; 95 % CI = 1.010–3.901). The other gene variants –
including blood type, alpha thalassemia, and SLCO1B1 – carried no significant risk.
Conclusions: G6PD deficiency, short HO-1 promoter GT-repeat and GA at nt211 in UGT1A1 are risk factors of
neonatal hyperbilirubinemia. The data provide clinical evidence to explain the high incidence of neonatal
hyperbilirubinemia in Taiwan.
Keywords: Neonatal hyperbilirubinemia, Heme oxygenase-1, UDP-glucuronosyltransferase 1A1, Thalassemia,
Hepatic solute carrier organic anion transporter 1B1
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Background
Hyperbilirubinemia is a common disorder during neonatal
period. It is associated with a variety of physiologic and
pathologic conditions [1]. Common factors in relation to
neonatal hyperbilirubinemia are breast milk feeding,
isoimmune hemolytic disease and G6PD deficiency [2–5].
In addition, other gene variants – including heme oxygen-
ase (HO)-1, hepatic solute carrier organic anion trans-
porter 1B1 (SLCO1B1), and UDP-glucuronosyltransferase
1A1 (UGT1A1)—have been reported as risk factors of
neonatal hyperbilirubinemia [6–9].
Asian infants are at greater risk of hyperbilirubine-
mia [10]. Gene variants may play an important role in
the development of neonatal hyperbilirubinemia. In
the current study, we examined 6 genetic variants
involving the production and metabolism of bilirubin
to verify their correlation with neonatal hyperbilirubi-
nemia. Our data will provide clinical evidence to explain
the high incidence of neonatal hyperbilirubinemia in
Taiwan.
* Correspondence: yihaoweng@adm.cgmh.org.tw
1Division of Neonatology, Department of Pediatrics, Chang Gung Memorial
Hospital, Chang Gung University College of Medicine, 199 Dunhua North
Road, Taipei 105, Taiwan
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Healthy infants born in the Chang Gung Memorial
Hospital at Taipei between January 2013 and August
2015 were eligible for enrollment. Infants with gestational
age less than 35 weeks and birth weight less than 2000 g
were not enrolled since they carry great risk for neonatal
hyperbilirubinemia. In addition, ill neonates admitted to
neonatal intensive care unit (NICU) were excluded. The
Institutional Review Board of Chang Gung Memorial
Hospital approved the study protocol. Informed consent
was obtained from parents of enrolled infants.
Clinical measures
Infants were routinely observed visually for the develop-
ment of significant clinical jaundice. Bilirubin level was
screened daily in all infants with non-invasive transcu-
taneous bilirubinmeter BiliCheck device (Spectrx Inc,
Norcross, GA, USA) [11]. Serum bilirubin tests were
performed with UnistatTM bilirubinmeter (Cambridge
Instruments, NY, USA). The protocol of phototherapy
was modified from the guideline of 2004 American
Academy of Pediatrics [12], as indicated for preterm in-
fants < 37 weeks of gestation (≥7 mg/dL at < 24 h old, ≥
9 mg/dL at 24–35 h old, ≥ 10 mg/dL at 36–47 h old, ≥
12 mg/dL at 48–59 h old, ≥ 13 mg/dL at 60–71 h old, ≥
14 mg/dL at 72–95 h old, and ≥ 15 mg/dL at ≥ 96 h old)
and term infants (≥9 mg/dL at < 24 h old, ≥ 11 mg/dL at
24–35 h old, ≥ 12 mg/dL at 36–47 h old, ≥ 14 mg/dL at
48–59 h old, ≥ 15 mg/dL at 60–71 h old, ≥ 16 mg/dL at
72–95 h old, and ≥ 17 mg/dL at ≥ 96 h old). Hyperbilirubi-
nemia was defined as total bilirubin ≥ 15 mg/dL during
the hospital course [8].
Demographic data — including gender, delivery mode,
birth weight and gestational age—were collected from
birth records. The feeding type was classified into three
categories: (1) formula feeding; (2) combination feeding
of breast milk and formula, defined as at least one meal
of breast milk and formula daily; (3) breast milk feeding.
Laboratory measures
This study examined the following genes – including
G6PD, blood type (ABO and Rh), HO-1, UGT1A1, alpha
thalassemia, and SLCO1B1. All infants were screened
for G6PD deficiency on the second day of life with blood
samples from heel stick as a routine part of Taiwan’s na-
tional newborn screening program. The quantitative test
for G6PD activity of red blood cells was performed to
confirm the diagnosis of G6PD deficiency in those who
had positive results from screening [2]. Blood type (ABO
and Rh) was examined using a commercially available
kit (Immucor Gamma, Norcross, GA, USA).
Total genomic DNA was isolated from cord blood
cells by using the Puregene DNA Isolation Kit (Qiagen,
Minneapolis, MN). The polymerase chain reaction
(PCR) mixture comprises 10 mM Tris (pH 9.0), 50 mM
KCL, 200 mM dNTPs, 1.25 mM MgCl2, 10 pmol each
of primers, 20 μl DNA and 1 U Taq DNA polymerase
(Gibco BRL). PCR is carried out in an automated ther-
mocycler with optimal conditions. Restriction fragment
length polymorphism (RFLP) and sequencing from
products of PCR were conducted as means of detecting
the known gene variants [8].
The HO-1 promoter gene containing GT repeats was
amplified by PCR with a sense primer (5’-AGA GCC
TGC AGC TTC TCA GA-3’) and an antisense primer
(5’-ACA AAG TCT GGC CAT AGG AC-3’) according
to a published protocol [13]. PCR products were ana-
lyzed in an automated DNA sequencer (ABI Prism 377,
Foster City, CA). Sizes of GT repeats were calculated
using GeneScan Analysis software (PE Applied Biosystems,
Foster City, CA). To detect the alpha thalassemia-1 of
Southeast Asia type, PCR was performed using the follow-
ing primers – (a) 5` - GCG ATC TGG GCT CTG TGT
TCT - 3`; (b) 5` - GTT CCC TGA GCC CCG ACA CG -
3`; (c) 5` - ACT GCA GCC TTG AAC TCC TG - 3` [14].
In addition, SLCO1B1 gene containing nt388 variant
was amplified by PCR with a sense primer (5’-ATA
ATG GTG CAA ATA AAG GGG-3’) and an antisense
primer (5’-ACT ATC TCA AGG TGA TGC TCT A-3’)
[15]. Furthermore, UGT1A1 gene containing nt211 vari-
ant was amplified by PCR with a sense primer (5’-CTC
TAA GCA CAT CCC CAA GTA-3’) and an antisense
primer (5’-TAA GCA AGT TTC CAT CCT TCA-3’) [15].
Statistical analyses
The statistics were compiled using a commercially available
program (SPSS 19.0 for Windows, SPSS Inc., Chicago,
Illinois, USA). Categorical variables were analyzed using
the chi-square test. For comparison between groups with
quantitative variables, the null hypothesis that there was
no difference between each group was tested by a one‐way
analysis of variance (ANOVA). A log-binomial model
(generalized linear model with a log link and a binomial
distribution for the error term) was used to estimate the
risk of neonatal hyperbilirubinemia in relation to gene var-
iants after adjusting for possible confounders of neonatal
factors – including feeding type, delivery mode, and
gestational age. Relative risk with 95 % confidence in-
tervals (CI) was expressed after adjusting for the con-
trol variables. Significance was defined as p < 0.05.
Results
Demographic information
Of the 520 parents approached for participation, 444
infants (85.4 %) were enrolled into this study. Their
demographic data are listed in Table 1. The incidence of
neonatal hyperbilirubinemia was 22.5 % (100/444). Only
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a few participants were preterm (3.6 %) and low birth
weight infants (<2500 g) (0.9 %). Neonatal hyperbiliru-
binemia was noted in 100 infants (22.5 %). There was
no significant difference in the gender, delivery mode,
gestational age, birth weight, and feeding type between
infants with and without hyperbilirubinemia.
Correlation of gene variants with neonatal
hyperbilirubinemia
According to the classification of previous reports [16, 17],
we divided the number of GT alleles into two categories:
short (<24 repeats) and long (≥24 repeats) alleles. In total,
the most common genetic variant was short HO-1 pro-
moter GT-repeat (39.4 %), followed by GA at nt388 in
SLCO1B1 (31.1 %), GA at nt211 in UGT1A1 (29.3 %),
ABO incompatibility (defined as neonates with A or B
blood type born to type O mothers [18]) (16.2 %), alpha
thalassemia (5.0 %), G6PD deficiency (3.2 %), and Rh
negative (0 %).
Table 2 illustrates the correlation of gene variants with
neonatal hyperbilirubinemia. There was a significant
correlation of neonatal hyperbilirubinemia with HO-1
promoter GT-repeat and nt211 in UGT1A1. Short HO-1
promoter GT-repeat and GA at nt211 in UGT1A1 were at
greater risk of hyperbilirubinemia.
Risk assessment by a log-binomial model
A log-binomial analysis to assess the risk of hyperbiliru-
binemia is shown in Table 3. There were greater risks of
neonatal hyperbilirubinemia in infants with G6PD
deficiency, short HO-1 promoter allele, and GA at nt211
in UGT1A1.
Discussion
The current study depicts the correlation of gene variants
with neonatal hyperbilirubinemia in Taiwan. We used a
log-binomial model to control the possible confounding
factors. In addition, our study investigated six different
genes involving the production and metabolism of
bilirubin. Furthermore, we selected common gene variants
in an attempt to explain the high incidence of neonatal
hyperbilirubinemia in Taiwan. The data showed 3 gene
variants – including G6PD deficiency, GA at nt211 in
UGT1A1, and short HO-1 promoter GT-repeat – carried
great risks for hyperbilirubinemia. To our knowledge, our
study is the first prospective survey to determine the
correlations of neonatal hyperbilirubinemia with HO-1
promoter GT-repeat and alpha-thalassemia in Taiwan.
HO is the rating-limiting enzyme to catalyze heme
into bilirubin [19]. HO-1, one of HO isoforms, has been
regarded as an inducible antioxidant [20]. The size of
GT-repeat alleles in the HO-1 promoter can alter the
inducibility of HO-1 [21]. Thus, a number of studies tried
to verify the association between HO-1 promoter GT-
repeat and neonatal jaundice. However, the results are still
controversial [7, 16, 17, 22–25]. In our study, HO-1
promoter GT allele was relevant to neonatal hyperbilirubi-
nemia. Our data demonstrated short HO-1 promoter
GT-repeat is the most common gene variant. Thus, we
speculate gene variants of HO-1 promoter GT allele
Table 1 Demographic data of participants
Demographics Hyperbilirubinemia p
valueDemographics Yes No
N = 100 N = 344
Male sex 51 (51.0 %) 185 (53.8 %) 0.624
Cesarean section 27 (27.0 %) 112 (32.6 %) 0.291
Preterm 4 (4.0 %) 12 (3.5 %) 0.809
Birth weight (g) 3211 ± 330 3226 ± 372 0.715
Feeding type 0.814
Breast milk 52 (52.0 %) 192 (55.8 %)
Formula 3 (3.0 %) 14 (4.1 %)
Combination 45 (45.0 %) 138 (40.1 %)
Table 2 Correlation of gene variants with neonatal
hyperbilirubinemia by univariate analysis
Gene variant Hyperbilirubinemia p
valueYes No
N = 100 N = 344
ABO incompatibility 17 (17.0 %) 55 (16.0 %) 0.809
G6PD deficiency 6 (6.0 %) 8 (2.3 %) 0.096
Alpha thalassemia 4 (4.0 %) 18 (5.2 %) 0.796
UGT1A1 (nt211) 0.015
GA 39 (39.0 %) 91 (26.5 %)
GG 61 (61.0 %) 253 (73.5 %)
SLCO1B1 (nt388) 0.449
GA 28 (28.0 %) 110 (32.0 %)
GG 72 (72.0 %) 234 (68.0 %)
HO-1 promoter (GT)n allele
< 24 repeats (short) 59 (59.0 %) 116 (33.7 %) <0.001
≥ 24 repeats (long) 41 (41.0 %) 228 (66.3 %)
Table 3 Risk assessment of gene variants for neonatal
hyperbilirubinemia by log-binomial analysis (n = 444)
Gene variant Relative risk 95 % CI p value
ABO incompatibility 1.075 0.685–1.687 0.754
G6PD deficiency 1.985 1.010–3.901 0.047
Alpha thalassemia 0.619 0.252–1.519 0.295
GA at nt211 in UGT1A1 1.548 1.096–2.187 0.013
GA at nt388 in SLCO1B1 0.921 0.627–1.353 0.675
Short HO-1 promoter GT-repeat 2.185 1.527–3.125 <0.001
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contribute to the high prevalence of neonatal hyperbiliru-
binemia in the population of Taiwan.
UGT1A1 is an enzyme responsible for bilirubin
conjugation. A missense mutation of G to A at nt211 in
UGT1A1 is common [26]. Our study demonstrated that
GA at nt211 in UGT1A1 is associated with neonatal
hyperbilirubinemia, which is consistent with a number
of previous reports [8, 26–28]. However, a correlation of
GA at nt211 in UGT1A1 with neonatal hyperbilirubine-
mia was not noted in Caucasian population [27, 29].
Further study is needed to verify the difference between
ethnicities.
It’s well documented that G6PD deficiency is a risk
factor of neonatal hyperbilirubinemia [2, 3, 12]. In our
study, the incidence of G6PD deficiency in infants with
hyperbilirubinemia was 2.6-fold higher than that of infants
without hyperbilirubinemia. However, the univariate
analysis did not show a statistical difference. Nevertheless,
the log-binomial analysis demonstrated a significant cor-
relation of G6PD deficiency with neonatal hyperbilirubi-
nemia after adjusting other confounding factors. In our
study, infants with G6PD deficiency are at an increased
risk for hyperbilirubinemia in the first few days of life even
in the hospital free from agents that can potentially cause
destruction of G6PD-deficient red cells. The data support
our previous report in a large scale of population showing
that neonatal hyperbilirubinemia in relation to G6PD
deficiency is not associated with hemolysis [2].
SLCO1B1, also named as OATP2, is responsible for
the transportation of unconjugated bilirubin. A relation-
ship between nt388 in SLCO1B1 and neonatal hyper-
bilirubinemia has been documented [15, 30]. However,
such correlation is in debate [8]. In this study, we did
not find significant correlation of nt388 in SLCO1B1
with hyperbilirubinemia.
Our data indicate alpha thalassemia is not a risk factor
of hyperbilirubinemia. The finding is similar to a retro-
spective report showing the incidence of hyperbilirubi-
nemia was lower in the infants with alpha thalassemia
[31]. We speculate that the destruction of red cells in
infant with alpha thalassemia was decreased as a result
of insufficient production of red cells. Therefore, their
production of bilirubin was lower than infants without
alpha thalassemia.
Blood group mismatch between a mother and newborn
carries a substantial risk for neonatal hyperbilirubinemia
[18]. However, we did not find blood group incompatibil-
ity as a significant factor of hyperbilirubinemia. We specu-
late three possible reasons. First, Rh incompatibility is very
rare in Taiwan. Second, hemolytic anemia is not common
in ABO incompatibility. Third, early phototherapy may
reduce the development of hyperbilirubinemia. Therefore,
we found a discrepancy of genetic influence between
phototherapy and hyperbilirubinemia (data not shown).
Taken together, we suggest that blood group incompatibil-
ity has only mild impact on the high incidence of neonatal
hyperbilirubinemia in Taiwan.
A couple of methodological issues should be cautiously
interpreted in this study. First, the sample size was
relatively small in infants with hyperbilirubinemia. Never-
theless, the statistical power using the G Power 3.1 pro-
gram to detect a significant association in HO-1 promoter
allele was 99.1 %, which indicating sufficient power to
achieve a low risk of type II error. Second, we enrolled
infants whose parents were willing to participating in this
study. One would question whether the gene variants in
this design carry expected frequency. We believe the
selection bias is minimal because of similar frequency with
previous reports in Taiwan [2, 8, 13, 14, 18, 26].
Conclusions
There are some critical findings in this study. We show
G6PD deficiency, GA at nt211 in UGT1A1, and short
HO-1 promoter GT-repeat possess great risks for neo-
natal hyperbilirubinemia. In contrast, the other 3 gene
variants – including alpha thalassemia, blood group in-
compatibility, and SLCO1B1—are not related to hyperbilir-
ubinemia. The findings suggest that a high incidence of
neonatal hyperbilirubinemia in Taiwan may be derived
from high prevalence of gene variants in G6PD, nt211 in
UGT1A1, and HO-1 promoter GT-repeat. Overall, our
data provide clinical implication of identifying infants at
great risk of neonatal hyperbilirubinemia. Early interven-
tion and close monitor are helpful in reducing severe
hyperbilirubinemia for infants with G6PD deficiency, short
HO-1 promoter GT-repeat, and GA at nt211 in UGT1A1.
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